Can This Stock Double Again in 2026?

• Structure Therapeutics' affirmative signifier 2 information for aleniglipron sent its banal terms soaring past year.

• The medicine could articulation the fast-growing value nonaccomplishment market, but it volition look plentifulness of competition.

• The clinical-stage biotech could spot its shares plummet should determination beryllium immoderate objective setback.

• 10 stocks we similar amended than Structure Therapeutics ›

Structure Therapeutics (NASDAQ: GPCR) ended 2025 connected a beardown note. Shares of the clinical-stage biotech soared successful December aft it reported beardown mid-stage information for its starring pipeline candidate, an investigational value nonaccomplishment medicine called aleniglipron. If Structure Therapeutics tin marque much advancement toward entering the fast-growing anti-obesity marketplace this year, we could spot the institution carrying the momentum it had past twelvemonth done 2026.

But tin the banal truly present the kinds of returns it did past year? And is it worthy investing successful for those focused connected the agelong game? Let's find out.

Aleniglipron is simply a once-daily oral GLP-1 candidate. In a 36-week signifier 2b study, the medicine posted a competitory placebo-adjusted mean value nonaccomplishment of 11.3% astatine the highest dose. In different ongoing mid-stage survey featuring adjacent higher doses of the drug, investigators observed a mean value nonaccomplishment of up to 15.3% aft 36 weeks. There was a 10.4% discontinuation complaint owed to adverse reactions successful the archetypal study, but that's beauteous communal with GLP-1 medicines.

Overall, tolerability was good wrong the norm for this people of drugs. Based connected these results, Structure Therapeutics plans to initiate a signifier 3 survey for aleniglipron, apt this year. Structure Therapeutics does person different candidates successful its pipeline. It precocious initiated a signifier 1 survey for ACCG-2671, an oral value nonaccomplishment campaigner that mimics the enactment of the amylin hormone, which plays a relation successful regulating humor sweetener and promoting satiety; it is progressively becoming a people for drugmakers looking to make breakthrough anti-obesity medicines.

Aleniglipron inactive has a agelong mode to spell earlier earning regulatory approval. In the meantime, it whitethorn brushwood important objective oregon regulatory hurdles. True, it is taken orally, giving it a flimsy borderline implicit immoderate of the starring value absorption therapies connected the market, which are administered subcutaneously. Many patients volition similar pills implicit needles. And the erstwhile thin to beryllium easier to manufacture, store, and transport, allowing them to beryllium sold astatine little prices.

However, by the clip aleniglipron gets to the market, determination should beryllium astatine slightest 2 different oral medicines already approved. The U.S. Food and Drug Administration precocious approved an oral formulation of Wegovy. It is besides reviewing an exertion for orforglipron, different oral medicine, this 1 developed by Eli Lilly.